Cost and Customer-Response Risks from Applying the Ordinance on Prevention of Hazards Due to Specified Chemical Substances to Antimony Trioxide
First written in FY2017. 16 of 17 entries say "Restated". Latest entry: FY2024-Q3.
The whole theme swung hardest in 2022: 4 of 8 companies on the "Worse" side.
15 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「During the nine-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The disclosure states that there have been no new developments or material changes in the cost and customer-response risks arising from antimony trioxide becoming subject to the Specified Chemicals Ordinance. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no new business risks and no material changes to the business risks described in the securities report for the previous fiscal year.」
The disclosure states that there have been no new developments or material changes in the cost and customer-response risks arising from antimony trioxide becoming subject to the Specified Chemicals Ordinance. - FY2023-Q3RestatedAnnual report
「During the nine-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The disclosure states that there have been no new developments or material changes in the cost and customer-response risks arising from antimony trioxide becoming subject to the Specified Chemicals Ordinance. - FY2021RestatedAnnual report
「Antimony trioxide, a major product of this business, was added to the Class 2 controlled substances under the Ordinance on the Prevention of Hazards Due to Specified Chemical Substances (hereinafter, the “Specified Chemicals Ordinance”) effective 1 June 2017. As a result, our facilities are required to implement measures to control the release of the substance, conduct work-environment monitoring and special medical examinations, among other measures. Customers using the product may also newly be required to take similar measures.」
The disclosure continues to describe the response burden and cost risks for the Company and its customers arising from application of the Specified Chemicals Ordinance. - FY2021-Q3RestatedAnnual report
「During the nine-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The disclosure states that there have been no material changes in the cost and customer-response risks arising from antimony trioxide becoming subject to the Specified Chemicals Ordinance. - FY2021-Q2RestatedAnnual report
「During the six-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes in the cost and customer-response risks arising from antimony trioxide becoming subject to the Specified Chemicals Ordinance. - FY2021-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The disclosure states that there have been no material changes in the cost and customer-response risks arising from antimony trioxide becoming subject to the Specified Chemicals Ordinance. - FY2020-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
No material changes are reported regarding the cost and customer-response risks associated with antimony trioxide being subject to the Specified Chemical Substances Ordinance. - FY2019RestatedAnnual report
「Antimony trioxide, a major product of the business, was added to the Category 2 controlled substances under the Ordinance on Prevention of Health Impairment Due to Specified Chemical Substances (the “Specified Chemical Substances Ordinance”) effective 1 June 2017.」
The disclosure continues to describe the response risks for the Company and its customers arising from antimony trioxide becoming subject to the Specified Chemicals Ordinance. - FY2019-Q3RestatedAnnual report
「During the nine-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
No material changes are reported regarding the cost and customer-response risks associated with antimony trioxide being subject to the Specified Chemical Substances Ordinance. - FY2019-Q2RestatedAnnual report
「During the six-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
No material changes are reported regarding the cost and customer-response risks associated with antimony trioxide being subject to the Specified Chemical Substances Ordinance. - FY2019-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
No material changes are reported regarding the cost and customer-response risks associated with antimony trioxide being subject to the Specified Chemical Substances Ordinance. - FY2018RestatedAnnual report
「Antimony trioxide, the principal product of this business, was added to Category 2 controlled substances under the Ordinance on Prevention of Hazards Due to Specified Chemical Substances on 1 June 2017. As a result, measures to control emissions, work-environment measurements and special medical examinations became necessary at our facilities, and customers using the product may also be required to take similar measures.」
The risks associated with the company's and customers' response to facility, monitoring and medical-examination requirements arising from the Specified Chemical Substances Ordinance continue to be disclosed. - FY2018-Q3RestatedAnnual report
「During the nine-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
No material changes are reported regarding the cost and customer-response risks associated with antimony trioxide being subject to the Specified Chemical Substances Ordinance. - FY2018-Q2RestatedAnnual report
「During the six-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
No material changes are reported regarding the cost and customer-response risks associated with antimony trioxide being subject to the Specified Chemical Substances Ordinance. - FY2018-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
No material changes are reported regarding the cost and customer-response risks associated with antimony trioxide being subject to the Specified Chemical Substances Ordinance. - FY2017First statedAnnual report
「Antimony trioxide, the principal product of this business, was added to Category 2 controlled substances under the Ordinance on Prevention of Hazards Due to Specified Chemical Substances on 1 June 2017. As a result, measures to control emissions, work-environment measurements and special medical examinations became necessary at our facilities, and customers using the product may also be required to take similar measures.」
The addition of antimony trioxide to Category 2 controlled substances under the ordinance created new risks involving the facilities, measurements, medical examinations and related costs of the Company and its customers.